Psychedelic-assisted drug developer MAPS PBC nabs $100M, renames to Lykos Therapeutics

Kyle LaHucik

Senior Reporter

MAPS Public Benefit Corporation, a California biotech attempting to bring MDMA-assisted therapy to market for mental health conditions, said it has raised more than …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Psychedelic-assisted drug developer MAPS PBC nabs $100M, renames to Lykos Therapeutics

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

At least seven drugmakers say they will participate in round two of IRA negotiations

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen

How AI can address ongoing challenges in the life sciences industry

Psy­che­del­ic-as­sist­ed drug de­vel­op­er MAPS PBC nabs $100M, re­names to Lykos Ther­a­peu­tics

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Psychedelic-assisted drug developer MAPS PBC nabs $100M, renames to Lykos Therapeutics